Online inquiry

IVTScrip™ mRNA-Human ALYREF, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK19645MR)

This product GTTS-WK19645MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ALYREF protein. This product can be used in Natural killer T (NKT) cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Human
RefSeq NM_005782.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 10189
UniProt ID Q86V81
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ALYREF, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WK19645MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK26810MR IVTScrip™ mRNA-Human ARHGEF16, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ARHGEF16
GTTS-WK12511MR IVTScrip™ mRNA-Human ADAP2, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ADAP2
GTTS-WK20857MR IVTScrip™ mRNA-Human AMOTL2, (Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMOTL2
GTTS-WK24305MR IVTScrip™ mRNA-Human Apelin, (Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Apelin
GTTS-WK18197MR IVTScrip™ mRNA-Human ANKRD10, (Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ANKRD10
GTTS-WK27775MR IVTScrip™ mRNA-Human ARRB1, (Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ARRB1
GTTS-WK26189MR IVTScrip™ mRNA-Human ARHGAP24, (Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ARHGAP24
GTTS-WK26891MR IVTScrip™ mRNA-Human ASAP1, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ASAP1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW